In this second renewal we propose to pursue three new areas of investigation that are a direct consequence of advances made during the previous funding period.
In Aims 1 and 2 we will further define the role that SHIP plays in NK effector function with a focus on cytokine production and NK tolerance to host.
In Aim 3 we will capitalize on our recent identification of the first small molecules that can selectively target SHIP1 activity in vivo to determine if this novel compound can enhance cancer control by NK cells.
The specific aims are:
Aim 1 : Determine the molecular basis for defective cytokine production by SHIP-/- NK cells. During the previous funding period we made the unexpected observation that SHIP is required for effective induction of 3-IFN by major NK activating receptors like NK1.1, NCR1/NKp46 and NKG2D. In this aim we will determine how broadly SHIP- deficiency impairs production of 3-IFN and other cytokines and chemokines produced by NK cells. In addition, we will define the molecular basis of this defect.
Aim 2 : Define the role of SHIP in self tolerance by the NK cell compartment. During the previous funding period we found that the expression and representation of both murine (Ly49) and human (KIR) NK inhibitory receptors for MHC class I ligands is limited by SHIP and that SHIP preferentially plays this role in the context of high affinity MHC-I ligands for these receptors. In the case of human KIR, we provide preliminary evidence that SHIP is required to maintain NK tolerance to the host. In this aim we will determine if SHIP plays a role in NK tolerance to self and does so in the context of MHC-I ligands that vary in their affinity for NK inhibitory receptors.
Aim 3 : Test the potential of SHIP inhibitors to enhance NK cell eradication of cancer. During the previous funding period we developed the first small molecule inhibitors of SHIP enzyme activity, one of which is selective for SHIP1 and has significant activity in vivo. In addition, we demonstrated that SHIP-/- NK cells from an MHC haplotype with a high affinity MHC-I ligand demonstrate supernormal killing of allogeneic tumors that lack this ligand. SHIP is also known to limit ADCC against tumor cells by NK cells. Thus, in this aim we will determine if chemical inhibition of SHIP can improve the ability of NK cells to eradicate cancer in vivo. This will be examined in three different contexts each of which has significant potential for translation to clinical therapy.

Public Health Relevance

In this proposal we will attempt to better understand why a gene called SHIP is important for certain immune cells, called natural killer cells, to fight injection and kill tumor cells. These approaches could lead to better ways to eradicate cancer using new chemicals we have discovered that can 'turn off'SHIP.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-VH-C (02))
Program Officer
Thomas, John
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Upstate Medical University
Schools of Medicine
United States
Zip Code
Iyer, Sonia; Viernes, Dennis R; Chisholm, John D et al. (2014) SHIP1 regulates MSC numbers and their osteolineage commitment by limiting induction of the PI3K/Akt/?-catenin/Id2 axis. Stem Cells Dev 23:2336-51
Maxwell, M J; Srivastava, N; Park, M-Y et al. (2014) SHIP-1 deficiency in the myeloid compartment is insufficient to induce myeloid expansion or chronic inflammation. Genes Immun 15:233-40
Park, M Y; Srivastava, N; Sudan, R et al. (2014) Impaired T-cell survival promotes mucosal inflammatory disease in SHIP1-deficient mice. Mucosal Immunol 7:1429-39
Fernandes, Sandra; Iyer, Sonia; Kerr, William G (2013) Role of SHIP1 in cancer and mucosal inflammation. Ann N Y Acad Sci 1280:6-10
Iyer, Sonia; Margulies, Bryan S; Kerr, William G (2013) Role of SHIP1 in bone biology. Ann N Y Acad Sci 1280:11-4
Montaudouin, Caroline; Anson, Marie; Hao, Yi et al. (2013) Quorum sensing contributes to activated IgM-secreting B cell homeostasis. J Immunol 190:106-14
Fuhler, Gwenny M; Brooks, Robert; Toms, Bonnie et al. (2012) Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med 18:65-75
Hadidi, S; Antignano, F; Hughes, M R et al. (2012) Myeloid cell-specific expression of Ship1 regulates IL-12 production and immunity to helminth infection. Mucosal Immunol 5:535-43
Kerr, William G; Park, Mi-Young; Maubert, Monique et al. (2011) SHIP deficiency causes Crohn's disease-like ileitis. Gut 60:177-88
Hazen, Amy L; Diks, Sander H; Wahle, Joseph A et al. (2011) Major remodelling of the murine stem cell kinome following differentiation in the hematopoietic compartment. J Proteome Res 10:3542-50

Showing the most recent 10 out of 27 publications